The Size of the Prize in Cardiovascular Disease (CVD) Prevention

Lancashire and South Cumbria





1. The diagnosis and treatment gap, 2015/16				
	Estimated adult population with hypertension	433,900		
	Estimated adult population with undiagnosed hypertension	175,900		
Hypertension	GP registered hypertensives not treated to 150/90 mmHg target	50,800		
	GP registered population with Atrial Fibrillation (AF)	33,200		
Atrial	Estimated GP registered population with undiagnosed AF	13,500		
Fibrillation (AF)	GP registered high risk AF patients (CHA2DS2VASc >=2) not anticoagulated	7,200		
A	Estimated adult population 30 to 85 years with 10 year CVD risk >20%	123,000		
CVD risk	Estimated percentage of people with CVD risk ≥20% treated with statins	49%		

2. The burden: first ever CVD events, 2015/16				
Coronary Heart Disease	5,000			
Stroke	2,250			
Heart Failure	1 650			

3. The opportunity: potential events averted and savings over 3 years by optimising treatment in AF and hypertension, 2015/16

Optimal anti-hypertensive treatment of diagnosed	300 heart attacks	Up to £2.20 million saved²
hypertensives averts within 3 years:	450 strokes	Up to £6.30 million saved ¹
Optimally treating high risk AF patients averts within 3 years:	580 strokes	Up to £9.70 million saved¹



What the evidence tells us

- Reducing blood pressure in all adults with diagnosed and undiagnosed hypertension by 5 mmHg: reduces risk of CVD events by 10%
- Statin therapy to reduce cholesterol by 1 mmol in people with a 10 year risk of CVD risk greater than 10%: reduces risk of CVD events by 20-24%
- Anti-coagulation of high risk AF patients: averts one stroke in every 25 treated



CVD: high risk conditions

High risk conditions like high blood pressure, atrial fibrillation and high cholesterol are major causes of heart attack and stroke (CVD events). In the high risk conditions preventive treatment is very effective, but late diagnosis and under-treatment is common.



Improving outcomes in CVD: case study

In Bradford Districts Clinical Commissioning Group: Over 24 months, more than 21,000 people had an intervention in lipid management, anti-coagulation or antihypertensive treatment to improve their health. Resulting in 137 fewer heart attacks and 74 fewer strokes compared to baseline.

Potential events calculated with NNT (theNNT.com). For blood pressure, anti-hypertensive medicines for five years to prevent death, heart attacks, and strokes: 1 in 100 for heart attack, 1 in 67 for stroke. For AF, warfarin over 1.5 years: 1 in 25 for stroke. Numbers may be lower, as some patients may be on prior treatment

¹ Royal College of Physicians (2016). Sentinel Stroke National Audit Programme. Cost and Cost-effectiveness analysis. Technical report

The graphic overleaf shows the size of the prize for CVD prevention in Lancashire and South Cumbria.

The estimates of impact are indicative but they show the scale of the opportunity to prevent heart attacks and strokes by improving the detection and management of high risk conditions like atrial fibrillation, high blood pressure and high cholesterol. Achieving this at scale would deliver substantial savings in health and social care spend.





The NHS RightCare programme is now rolling out the CVD Prevention Pathway with a series of high impact interventions that will support your CCGs to deliver this improvement. And increasing uptake of the NHS Health Check offers a systematic approach to detecting people with undiagnosed high risk conditions.

Cardiovascular Disease Prevention: Risk Detection and Management in Primary Care

Cross Cutting: 1. NHS Health Check systematic detection of high BP, AF, NDH, T2DM, CKD, high cholesterol, CVD risk 2. System level action to support guideline implementation by clinicians 3. Support for patient activation, individual behaviour change and self management The Interventions Detection, CVD risk Type 2 Diabetes High BP detection AF detection and Diabetes detection CKD detection assessment, preventive and treatment anticoagulation and management and treatment intervention treatment 30% undiagnosed. 85% of FH 5 million undiagnosed. 940k undiagnosed. 1.2m undiagnosed. 5 million un-The undiagnosed & most diagnosed - 40% Most do not receive 40% do not receive Many have poor BP Over half untreated people at high CVD risk **Opportunities** & proteinuria control poorly controlled or poorly controlled intervention all 8 care processes do not receive statins Control of BP, HbA1c Control of BP, CVD **BP** lowering Behaviour change Intensive behaviour Anticoagulation The Evidence prevents strokes prevents 2/3 of and statins reduce change (eg NHS DPP) and lipids improves risk and proteinuria CVD outcomes and heart attacks strokes in AF life time risk of CVD reduces T2DM risk 30-60% improves outcomes Blood High CVD risk & **NDH** Type 1 and 2 **Chronic Kidney Atrial** The Risk **Pressure Fibrillation** Familial H/cholesterol. ('pre-diabetes') **Diabetes** Disease Condition Detection and 2°/3° Prevention

etection and 2°/3° Prevention

Outcomes

50% of all strokes & heart attacks, plus CKD & dementia

5-fold increase in strokes, often of greater severity Marked increase in premature death and disability from CVD

Marked increase in Type 2 DM and CVD at an earlier age Marked increase heart attack, stroke, kidney, eye, nerve damage Increase in CVD, acute kidney injury & renal replacement